Tesamorelin Dosage: The 2 mg Protocol Explained

Tesamorelin is the rare GH-axis peptide where a dosage question actually has an FDA-approved answer — but the answer is more precise, and more narrowly indicated, than the “2 mg a day” shorthand suggests. Unlike sermorelin, CJC-1295, or ipamorelin (all off-label, all dosed by clinic convention), tesamorelin is sold as an approved finished drug — EGRIFTA and EGRIFTA SV — with a real label, a real indication, and a real recommended dose. This guide walks through what that approved dose actually is, why the number on the vial changed, and where the popular “off-label tesamorelin” use departs from the evidence.

The FDA-approved dose, stated precisely

Tesamorelin is approved for one thing: the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy¹. That is the entire indication. The dose people remember is 2 mg subcutaneously once daily — and that is correct for the original EGRIFTA formulation, which is what the pivotal trials used.

Here is the nuance the “2 mg protocol” shorthand misses. The current product, EGRIFTA SV, is a more concentrated reformulation, and its label-recommended dose is 1.4 mg (0.35 mL of reconstituted solution) injected subcutaneously once daily¹. The label is explicit that this is not a dose reduction in effect: “the systemic exposure (Cmax and AUC) of tesamorelin is similar between the 1.4 mg dose of EGRIFTA SV and the 2 mg dose of EGRIFTA”¹. In other words, 1.4 mg of the new formulation delivers the same drug exposure as 2 mg of the old one — same exposure, different number on the vial. So the honest one-line answer is: the approved dose is once-daily subcutaneous tesamorelin sized to match 2 mg of original EGRIFTA, which is 1.4 mg as EGRIFTA SV.

It is given by subcutaneous injection into the abdomen, once daily, and — like all GHRH analogs — it works by prompting your own pituitary to release growth hormone in pulses rather than injecting GH directly. (For how that mechanism compares to the compounded peptides, see tesamorelin vs sermorelin and the three-way sermorelin vs tesamorelin vs ipamorelin.)

What the approved dose was actually tested to do

The 2 mg-equivalent daily dose isn't a guess — it's the dose carried through tesamorelin's pivotal program. In its Phase III NEJM trial, daily tesamorelin significantly reduced visceral adipose tissue (the deep fat around the organs) versus placebo while raising IGF-1 and improving lipids in people with HIV-associated fat accumulation². A second pivotal randomized trial confirmed it, with a roughly 11% reduction in visceral fat over 26 weeks alongside improved triglycerides³. A long-term extension established that the effect depends on continued dosing — when people stop, the visceral fat returns⁴ — and a separate randomized trial showed the same daily dose reduced liver fat and slowed fibrosis progression in HIV-associated fatty liver disease⁵. So the dose has a genuine outcome record, not just a hormone-marker record. (We catalog those proven effects in tesamorelin benefits: what the evidence shows.)

The label's own limits on what the dose is for

The same label that establishes the dose also draws hard boundaries — boundaries that off-label marketing tends to skip. Per the prescribing information: tesamorelin is not indicated for weight-loss management, because it has a weight-neutral effect; its long-term cardiovascular safety has not been established; and there are no data showing it improves antiretroviral compliance¹. That weight-neutral point is the one most often inverted in marketing: the drug shifts visceral fat in a specific HIV population, but the label does not support it as a general fat-loss or “body recomposition” drug.

Off-label dosing: where evidence ends and convention begins

Outside HIV lipodystrophy, tesamorelin is increasingly prescribed off-label — for general visceral-fat reduction, “GH optimization,” or anti-aging — often through compounding pharmacies and grey-market suppliers rather than as the approved EGRIFTA product. Off-label clinic protocols frequently copy the 1–2 mg-once-daily number from the label, sometimes with cycling. Two honest cautions apply. First, the favorable benefit-risk that the dose earned was established in HIV-associated lipodystrophy, a specific metabolic context; it does not automatically transfer to a healthy person seeking cosmetic fat loss. Second, compounded or research-grade tesamorelin is not the FDA-approved product — identity, purity, and dose accuracy are not guaranteed, so even a “correct” dose on paper may not be what's in the vial. And as with every GH-axis drug, the response shrinks in older and heavier people, whose pituitaries release less GH to the same stimulus⁶. The dose is the easy part; the off-label context is where the risk lives.

The honest bottom line

Tesamorelin is the one peptide in this category with a real, FDA-established dose: once-daily subcutaneous tesamorelin sized to 2 mg of original EGRIFTA — which is 1.4 mg as the reformulated EGRIFTA SV, the same systemic exposure under a different number¹. That dose has a genuine Phase III record for reducing visceral and liver fat in HIV-associated lipodystrophy²³⁵ — and a label that openly limits it: not for weight loss, cardiovascular safety not established¹. Everything beyond that indication is off-label, copied from the approved dose without the population or the product behind it. For the full picture, see tesamorelin benefits, the tesamorelin vs sermorelin comparison, our pillar guide to GH-axis evidence, and — if you're weighing where to source any of these peptides — our guide to the best sermorelin providers.